Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
BMC Vet Res ; 20(1): 133, 2024 Apr 03.
Artículo en Inglés | MEDLINE | ID: mdl-38570815

RESUMEN

BACKGROUND: Obesity is a serious disease with an alarmingly high incidence that can lead to other complications in both humans and dogs. Similar to humans, obesity can cause metabolic diseases such as diabetes in dogs. Natural products may be the preferred intervention for metabolic diseases such as obesity. The compound 1-deoxynojirimycin, present in Morus leaves and other sources has antiobesity effects. The possible antiobesity effect of 1-deoxynojirimycin containing Morus alba leaf-based food was studied in healthy companion dogs (n = 46) visiting the veterinary clinic without a history of diseases. Body weight, body condition score (BCS), blood-related parameters, and other vital parameters of the dogs were studied. Whole-transcriptome of blood and gut microbiome analysis was also carried out to investigate the possible mechanisms of action and role of changes in the gut microbiome due to treatment. RESULTS: After 90 days of treatment, a significant antiobesity effect of the treatment food was observed through the reduction of weight, BCS, and blood-related parameters. A whole-transcriptome study revealed differentially expressed target genes important in obesity and diabetes-related pathways such as MLXIPL, CREB3L1, EGR1, ACTA2, SERPINE1, NOTCH3, and CXCL8. Gut microbiome analysis also revealed a significant difference in alpha and beta-diversity parameters in the treatment group. Similarly, the microbiota known for their health-promoting effects such as Lactobacillus ruminis, and Weissella hellenica were abundant (increased) in the treatment group. The predicted functional pathways related to obesity were also differentially abundant between groups. CONCLUSIONS: 1-Deoxynojirimycin-containing treatment food have been shown to significantly improve obesity. The identified genes, pathways, and gut microbiome-related results may be pursued in further studies to develop 1-deoxynojirimycin-based products as candidates against obesity.


Asunto(s)
Diabetes Mellitus , Enfermedades de los Perros , Microbioma Gastrointestinal , Enfermedades Metabólicas , Morus , Humanos , Animales , Perros , 1-Desoxinojirimicina/farmacología , Extractos Vegetales/farmacología , Obesidad/tratamiento farmacológico , Obesidad/veterinaria , Diabetes Mellitus/veterinaria , Enfermedades Metabólicas/veterinaria , Hojas de la Planta
2.
Int J Mol Sci ; 25(5)2024 Feb 23.
Artículo en Inglés | MEDLINE | ID: mdl-38473839

RESUMEN

Leopoldia comosa (LC), popularly known as Muscari comosum, spontaneously grows in the Mediterranean region and its bulbs are used as a vegetable. Traditionally, they are also used to treat various diseases and conditions, which has inspired the study of the pharmacological activities of different parts of LC. These studies revealed the numerous biological properties of LC including antioxidant, anti-inflammatory, anti-diabetes, anti-obesity, anti-cancer, anti-Alzheimer's disease, antibacterial, and immune stimulant. High antioxidant activity compared to other non-cultivated plants, and the potential role of antioxidant activity in other reported activities make LC an excellent candidate to be developed as an antioxidant plant against important associated diseases. The presence of a diverse class of phytochemicals (n = 85), especially flavonoids and homoisoflavones, in LC, also imparts significance to the nutraceutical candidature of the plant. However, limited animal studies and the lack of a directional approach have limited the further design of effective clinical studies for the development of LC. The current study is the first attempt to comprehensively compile information regarding the phytochemicals and pharmacological activities of LC, emphasize the targets/markers targeted by LC, important in other activities, and also highlight the current gaps and propose possible bridges for the development of LC as a therapeutic and/or supplement against important diseases.


Asunto(s)
Antioxidantes , Asparagaceae , Animales , Antioxidantes/farmacología , Extractos Vegetales/farmacología , Flavonoides/farmacología , Fitoquímicos/farmacología
3.
Molecules ; 29(1)2023 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-38202771

RESUMEN

Shionone is a triterpenoid that is the primary constituent of an important ancient Chinese medicine named Radix Asteris. It has emerged as an attractive candidate against different important diseases, including interstitial cystitis, colitis, cancer, Parkinson's disease, and urinary tract infections, and was found to have a protective effect on multiple organs, including the colon, kidneys, lungs, brain, and bladder. The anti-inflammation activity of shionone may be considered an important property that imparts the positive health outcomes of shionone. Important molecular targets and markers such as TNF-α, STAT3, NLRP3, and NF-κB were also found to be targeted by shionone and were verified in different diseases. This suggests the possible potential of shionone against other diseases associated with these targets. Pharmacokinetic studies also support the therapeutic potential of shionone and provide the initial track that may be pursued for its development. Yet, the compilation of the pharmacological activities of shionone and its important genes and pathway targets are absent in the existing literature, which would direct its development as a therapeutic and/or supplement. Hence, the present review provides a compilation of information concerning pharmacological activities, highlights the existing holes, and proposes a specific direction for the expansion of shionone as a therapeutic against different diseases and conditions.


Asunto(s)
Antiinflamatorios , Fitoquímicos , Triterpenos , Humanos , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Triterpenos/farmacología , Triterpenos/uso terapéutico , Fitoquímicos/farmacología , Fitoquímicos/uso terapéutico
4.
Int J Mol Sci ; 23(23)2022 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-36499541

RESUMEN

Overweight and obesity, associated with various health complications, refer to abnormal or excessive fat accumulation conditions that harm health. Like humans, obesity is a growing problem in dogs, which may increase the risk of serious diseases such as diabetes and cancer. Mulberry leaf has shown potential anti-obesity and anti-diabetes effects in several studies. Our research studied the impact of mulberry leaf supplements in healthy old overweight dogs for 12 weeks. Blood and fecal samples were collected from the dogs before and after treatment for different analyses, including whole transcriptome and gut microbiome analysis. The Body Condition Score (BCS) and blood glucose levels were significantly decreased in all mulberry treatment groups, which justifies the anti-obesity effect of mulberry leaf in dogs. Throughout the whole transcriptome study, the downregulation of PTX3 and upregulation of PDCD-1, TNFRSF1B, RUNX3, and TICAM1 genes in the high mulberry group were found, which have been associated with anti-inflammatory effects in the literature. It may be an essential gene expression mechanism responsible for the anti-inflammatory and, subsequently, anti-obesity effects associated with mulberry leaf treatment, as confirmed by real-time polymerase chain reaction analysis. In microbiome analysis, Papillibacter cinnamivorans, related to the Mediterranean diet, which may cause anti-inflammatory effects, were abundant in the same treatment group. Further studies may be required to establish the gene expression mechanism and role of abundant bacteria in the anti-obesity effect of mulberry supplements in dogs. Overall, we propose mulberry leaves as a portion of food supplements for improving blood glucose levels and the anti-inflammation of blood in companion dogs.


Asunto(s)
Diabetes Mellitus , Morus , Humanos , Perros , Animales , Anciano , Glucemia , Hojas de la Planta/metabolismo , Obesidad/metabolismo , Sobrepeso/complicaciones , Suplementos Dietéticos , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico
5.
Genomics ; 112(1): 796-804, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31128264

RESUMEN

Malaria is a life-threatening disease causes huge burden on human health. Every year >200 million cases of malaria are reported globally. Researchers have carried out research on transcriptome of different stages of Plasmodium species to understand complex pathology of pathogens and to discover therapeutics. Researchers are targeting different stages of Plasmodium falciparum separately. Hence, to target all stages of Plasmodium simultaneously comparative transcriptome analysis of different stages was carried out and 44 commonly expressed proteins from different stages of Plasmodium were identified. These proteins were analyzed for their drug target and vaccine potential in different analysis. Conservation of these proteins in human infecting Plasmodium species was also studied. Current approach is also justified because few of these proteins were found to be known vaccine and drug target candidates in different infectious diseases. These proteins can be taken as drug targets and/or vaccine candidates in further experimentation against malaria.


Asunto(s)
Antígenos de Protozoos/inmunología , Plasmodium falciparum/genética , Plasmodium falciparum/inmunología , Proteínas Protozoarias/inmunología , Antígenos de Protozoos/química , Antígenos de Protozoos/genética , Antígenos de Protozoos/metabolismo , Antimaláricos , Epítopos de Linfocito B/química , Epítopos de Linfocito T/química , Humanos , Vacunas contra la Malaria/inmunología , Plasmodium falciparum/crecimiento & desarrollo , Dominios Proteicos , Proteínas Protozoarias/química , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , RNA-Seq , Homología de Secuencia de Aminoácido , Transcriptoma
6.
Bioorg Med Chem ; 28(1): 115155, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31744777

RESUMEN

Falcipains (FPs), cysteine proteases in the malarial parasite, are emerging as the promising antimalarial drug targets. In order to identify novel FP inhibitors, we generated a pharmacophore derived from the reported co-crystal structures of inhibitors of Plasmodium falciparum Falcipain-3 to screen the ZINC library. Further, the filters were applied for dock score, drug-like characters, and clustering of similar structures. Sixteen molecules were purchased and subject to in vitro enzyme (FP-2 and FP-3) inhibition assays. Two compounds showed in vitro inhibition of FP-2 and FP-3 at low µM concentration. The selectivity of the inhibitors can be explained based on the predicted interactions of the molecule in the active site. Further, the inhibitors were evaluated in a functional assay and were found to induce morphological changes in line with their mode of action arresting Plasmodium development. Compound 15 was most potent inhibitor identified in this study.


Asunto(s)
Antimaláricos/farmacología , Cisteína Endopeptidasas/metabolismo , Inhibidores Enzimáticos/farmacología , Plasmodium falciparum/efectos de los fármacos , Antimaláricos/química , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Simulación del Acoplamiento Molecular , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Plasmodium falciparum/enzimología , Relación Estructura-Actividad
7.
Bioorg Med Chem Lett ; 25(22): 5281-5, 2015 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-26428872

RESUMEN

The 3-substituted oxindole derivatives were designed, synthesized, and evaluated for antidepressant activity by employing forced swimming test, tail suspension test, and MAO-A inhibition assay. Results of biological studies revealed that the majority of compounds exhibited potent to moderately potent activity and among them, 12 displayed potency comparable to that of the imipramine with %DID of 37.95 and 44.84 in the FST and TST, respectively. At the same time, imipramine showed %DID of 43.62 and 50.64 in the FST and TST, correspondingly. In the MAO-A inhibition assay, 12 showed an IC50 of 18.27 µmol, whereas the reference drug moclobemide displayed an IC50 of 13.1 µmol. The SAR study disclosed that the presence of bromo atom at the phenyl/furanyl or thienyl moiety in the oxindole derivatives was critical for the antidepressant activity.


Asunto(s)
Antidepresivos/química , Compuestos de Bencilideno/química , Indoles/química , Lactamas/química , Inhibidores de la Monoaminooxidasa/química , Animales , Antidepresivos/síntesis química , Antidepresivos/farmacología , Compuestos de Bencilideno/síntesis química , Compuestos de Bencilideno/farmacología , Clorgilina/farmacología , Imipramina/farmacología , Indoles/síntesis química , Indoles/farmacología , Lactamas/síntesis química , Lactamas/farmacología , Ratones , Moclobemida/farmacología , Simulación del Acoplamiento Molecular , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/síntesis química , Inhibidores de la Monoaminooxidasa/farmacología , Relación Estructura-Actividad
8.
Bioinformatics ; 29(15): 1904-7, 2013 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-23716197

RESUMEN

MOTIVATION: Influenza is responsible for half a million deaths annually, and vaccination is the best preventive measure against this pervasive health problem. Influenza vaccines developed from surveillance data of each season are strain-specific, and therefore, are unable to provide protection against pandemic strains arising from antigenic shift and drift. Seasonal epidemics and occasional pandemics of influenza have created a need for a universal influenza vaccine (UIV). Researchers have shown that a combination of conserved epitopes has the potential to be used as a UIV. RESULT: In the present work, available data on strains, proteins, epitopes and their associated information were used to develop a Web resource, 'EpiCombFlu', which can explore different influenza epitopes and their combinations for conservation among different strains, population coverage and immune response for vaccine design. Forward selection algorithm was implemented in EpiCombFlu to select optimum combination of epitopes that may be expressed and evaluated as potential UIV. AVAILABILITY: The Web resource is freely available at http://117.211.115.67/influenza/home.html. CONTACT: chittaranjan.rout@juit.ac.in SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.


Asunto(s)
Epítopos/química , Vacunas contra la Influenza/inmunología , Programas Informáticos , Algoritmos , Epítopos/inmunología , Humanos , Internet , Orthomyxoviridae/clasificación , Orthomyxoviridae/inmunología , Análisis de Secuencia de Proteína , Proteínas Virales/química , Proteínas Virales/inmunología
9.
Mol Biol Rep ; 41(11): 7683-95, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25106526

RESUMEN

Jatropha (Jatropha curcas L.) and Castor bean (Ricinus communis) are oilseed crops of family Euphorbiaceae with the potential of producing high quality biodiesel and having industrial value. Both the bioenergy plants are becoming susceptible to various biotic stresses directly affecting the oil quality and content. No report exists as of today on analysis of Nucleotide Binding Site-Leucine Rich Repeat (NBS-LRR) gene repertoire and defense response transcription factors in both the plant species. In silico analysis of whole genomes and transcriptomes identified 47 new NBS-LRR genes in both the species and 122 and 318 defense response related transcription factors in Jatropha and Castor bean, respectively. The identified NBS-LRR genes and defense response transcription factors were mapped onto the respective genomes. Common and unique NBS-LRR genes and defense related transcription factors were identified in both the plant species. All NBS-LRR genes in both the species were characterized into Toll/interleukin-1 receptor NBS-LRRs (TNLs) and coiled-coil NBS-LRRs (CNLs), position on contigs, gene clusters and motifs and domains distribution. Transcript abundance or expression values were measured for all NBS-LRR genes and defense response transcription factors, suggesting their functional role. The current study provides a repertoire of NBS-LRR genes and transcription factors which can be used in not only dissecting the molecular basis of disease resistance phenotype but also in developing disease resistant genotypes in Jatropha and Castor bean through transgenic or molecular breeding approaches.


Asunto(s)
Sitios de Unión/genética , Resistencia a la Enfermedad/genética , Genoma de Planta/genética , Jatropha/genética , Secuencias Repetitivas de Aminoácido/genética , Ricinus/genética , Factores de Transcripción/genética , Mapeo Cromosómico , Perfilación de la Expresión Génica , Leucina , Receptores de Interleucina-1/genética
10.
Redox Biol ; 73: 103197, 2024 07.
Artículo en Inglés | MEDLINE | ID: mdl-38781730

RESUMEN

Astrocytes are the major glial cells in the human brain and provide crucial metabolic and trophic support to neurons. The amyloid-ß peptide (Aß) alter the morphological and functional properties of astrocytes and induce inflammation and calcium dysregulation, contributing to Alzheimer's disease (AD) pathology. Recent studies highlight the role of Toll-like receptor (TLR) 4/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in inflammation. Reactive oxygen species (ROS) generated due to Aß, induce apoptosis in the brain cells worsening AD progression. Astrocytic cell surface receptors, such as purinergic receptors (P2Y1 and P2Y2), metabotropic glutamate receptor (mGLUR)5, α7 nicotinic acetylcholine receptor (α7nAChR), and N-methyl-d-aspartate receptors (NMDARs), have been suggested to interact with inositol trisphosphate receptor (IP3R) on the endoplasmic reticulum (ER) to induce Ca2+ movement from ER to cytoplasm, causing Ca2+ dysregulation. We found that the citrus flavonoid nobiletin (NOB) protected primary astrocytes from Aß42-induced cytotoxicity and inhibited TLR4/NF-κB signaling in Aß42-induced primary rat astrocytes. NOB was found to regulate Aß42-induced ROS levels through Keap1-Nrf2 pathway. The receptors P2Y1, P2Y2, mGLUR5, α7nAChR, and NMDARs induced intracellular Ca2+ levels by activating IP3R and NOB regulated them, thereby regulating intracellular Ca2+ levels. Molecular docking analysis revealed a possible interaction between NOB and IP3R in IP3R regulation. Furthermore, RNA sequencing revealed various NOB-mediated biological signaling pathways, such as the AD-presenilin, AD-amyloid secretase, and Wnt signaling pathway, suggesting possible neuroprotective roles of NOB. To conclude, NOB is a promising therapeutic agent for AD and works by modulating AD pathology at various levels in Aß42-induced primary rat astrocytes.


Asunto(s)
Péptidos beta-Amiloides , Astrocitos , Calcio , Flavonas , Receptores de Inositol 1,4,5-Trifosfato , Astrocitos/metabolismo , Astrocitos/efectos de los fármacos , Péptidos beta-Amiloides/metabolismo , Animales , Receptores de Inositol 1,4,5-Trifosfato/metabolismo , Ratas , Calcio/metabolismo , Flavonas/farmacología , Especies Reactivas de Oxígeno/metabolismo , Fragmentos de Péptidos/farmacología , Fragmentos de Péptidos/metabolismo , Enfermedades Neuroinflamatorias/metabolismo , Enfermedades Neuroinflamatorias/tratamiento farmacológico , Humanos , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 4/metabolismo , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/patología
11.
J Biomol Struct Dyn ; 42(5): 2231-2241, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37116071

RESUMEN

For more than a century, the renin-angiotensin system (RAS) has been acknowledged for playing a crucial part in the physiological control of arterial pressure, as well as sodium and fluid balance. It is now generally acknowledged that one of the receptor of RAS system i.e. angiotensin type 2 receptor (AT2R) functions as a repair system during pathophysiologic circumstances and performs a significant protective role. Efforts have been made previously to design suitable agonist and antagonist molecules to potentially modulate AT2R. One of the agonists and antagonists, named C21 and EMA401, has been studied in a number of pathological conditions. Additionally, a wide panel of single nucleotide polymorphisms (SNPs) has been reported for AT2R, which might potentially affect the efficacy of these molecules. Therefore, computational investigations have been carried out to analyze all the SNPs (1151) reported in NCBI to find potential SNPs affecting the active site of AT2R, as this domain is still unexplored. Structures of these polymorphic forms were modeled, and in silico drug interaction studies with C21 and EMA401 were carried out. The two mutants (rs868939201 and rs1042852794) that significantly affect the binding affinity as that of the wild type were subjected to molecular dynamics simulations. Our analysis of native and mutant AT2R and their complexes with C21 and EMA401 indicated that the occurrence of these mutations affects the conformation of the protein and has affected the binding of these ligand molecules. The study's findings will aid in the development of better, more versatile medications in the near future, and also in vitro and in vivo studies might be planned in accordance with recent findings.Communicated by Ramaswamy H. Sarma.


Asunto(s)
Compuestos de Bencidrilo , Imidazoles , Isoquinolinas , Sistema Renina-Angiotensina , Sulfonamidas , Tiofenos , Receptor de Angiotensina Tipo 2/agonistas , Receptor de Angiotensina Tipo 2/genética , Receptor de Angiotensina Tipo 2/metabolismo
12.
Int Immunopharmacol ; 139: 112677, 2024 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-39024753

RESUMEN

High-molecular-weight fucoidan (Fucoidan P), sourced from Undaria pinnatifida exhibits several health benefits, including immunomodulation. However, the mechanisms underlying the immune-enhancing effects of Fucoidan P remain unclear. Here, we investigated the immune-enhancing effects and the potential mechanisms of Fucoidan P using RAW 264.7 macrophages and cyclophosphamide (CP)-induced immunosuppression rat model. In macrophages, Fucoidan P showed dose-dependent stimulation by increasing cell proliferation, nitric oxide production, and gene expression of inducible nitric oxide synthase, cyclooxygenase-2, and proinflammatory cytokines. These effects are mediated through the activation of the nuclear factor-kappa B (NF-κB) signaling pathway. Moreover, orally administered Fucoidan P was evaluated in immunosuppressed rats treated with CP. Fucoidan P administration increased hematological values and natural killer cell activity, and positively affected nitrite and prostaglandin E2 levels. The Fucoidan P treatment groups exhibited improved serum cytokine levels as well as splenic and intestinal cytokine mRNA expression compared to the model group. Fucoidan P also mitigated splenic damage and increased the phosphorylation of NF-κB and NF-κB inhibitor alpha (IκBα). Furthermore, Fucoidan P treatment altered the gut microbiota composition, enhancing the alpha diversity, evenness, and abundance of Bacteroidetes, which are associated with immune function. Taken together, our findings suggest that Fucoidan P exerts beneficial effects on immune function by activating NF-κB and modulating gut microbiota. These findings suggested its potential as a therapeutic agent for immune enhancement.


Asunto(s)
Ciclofosfamida , Citocinas , Microbioma Gastrointestinal , FN-kappa B , Polisacáridos , Animales , Polisacáridos/farmacología , Ratones , Microbioma Gastrointestinal/efectos de los fármacos , Células RAW 264.7 , Masculino , FN-kappa B/metabolismo , Ratas , Citocinas/metabolismo , Terapia de Inmunosupresión , Undaria/química , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Óxido Nítrico/metabolismo , Ratas Sprague-Dawley , Peso Molecular , Transducción de Señal/efectos de los fármacos , Bazo/efectos de los fármacos , Bazo/inmunología
13.
Artículo en Inglés | MEDLINE | ID: mdl-38275062

RESUMEN

BACKGROUND: Recognizing the potential of the immune system, immunotherapies have brought about a revolution in the treatment of cancer. Low tumour mutational burden and strong immunosuppression in the peritoneal tumor microenvironment (TME) lead to poor outcomes of immune checkpoint inhibition (ICI) and CART cell therapy in ovarian cancer. Alternative immunotherapeutic strategies are of utmost importance to achieve sound clinical success. INTRODUCTION: The development of peptide vaccines based on tumor-associated antigens (TAAs) for ovarian cancer cells can be a potential target to provoke an anti-tumor immune response and subsequent clearance of tumour cells. The purpose of this in silico study was to find potential epitopes for a multi-epitope vaccine construct using the immunopeptidomics landscape of ovarian carcinoma. METHODS: The four TAAs (MUC16, IDO1, FOLR1, and DDX5) were selected for potential epitopes prediction. The epitopes for B-cells, helper T-lymphocytes (HTL), and Cytotoxic Tlymphocytes (CTL) were predicted on the basis of antigenic, allergenic, and toxic properties. These epitopes were combined with suitable linkers and an adjuvant to form a multi-epitope construct. RESULTS: Four HTLs, 13 CTLs, and 6 potential B-cell epitopes were selected from the predicted epitope. The designed multi-epitope construct was potentially immunogenic, non-toxic, and non-allergenic. Physicochemical properties and higher-order structural analyses of the final construct revealed a potential vaccine candidate. CONCLUSION: The designed vaccine construct has the potential to trigger both humoral and cellular immune responses and may be employed as a therapeutic immunization candidate for ovarian malignancies. However, further in vitro and animal experimentation is required to establish the efficacy of the vaccine candidate.


Asunto(s)
Antígenos de Neoplasias , Vacunas contra el Cáncer , Simulación por Computador , Neoplasias Ováricas , Vacunas de Subunidad , Femenino , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/terapia , Humanos , Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/administración & dosificación , Antígenos de Neoplasias/inmunología , Vacunas de Subunidad/inmunología , Microambiente Tumoral/inmunología , Inmunoterapia/métodos , Epítopos/inmunología , Péptidos/inmunología , Péptidos/química , Epítopos de Linfocito B/inmunología , Epítopos de Linfocito T/inmunología
14.
BMC Bioinformatics ; 14: 211, 2013 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-23815072

RESUMEN

BACKGROUND: Subunit vaccines based on recombinant proteins have been effective in preventing infectious diseases and are expected to meet the demands of future vaccine development. Computational approach, especially reverse vaccinology (RV) method has enormous potential for identification of protein vaccine candidates (PVCs) from a proteome. The existing protective antigen prediction software and web servers have low prediction accuracy leading to limited applications for vaccine development. Besides machine learning techniques, those software and web servers have considered only protein's adhesin-likeliness as criterion for identification of PVCs. Several non-adhesin functional classes of proteins involved in host-pathogen interactions and pathogenesis are known to provide protection against bacterial infections. Therefore, knowledge of bacterial pathogenesis has potential to identify PVCs. RESULTS: A web server, Jenner-Predict, has been developed for prediction of PVCs from proteomes of bacterial pathogens. The web server targets host-pathogen interactions and pathogenesis by considering known functional domains from protein classes such as adhesin, virulence, invasin, porin, flagellin, colonization, toxin, choline-binding, penicillin-binding, transferring-binding, fibronectin-binding and solute-binding. It predicts non-cytosolic proteins containing above domains as PVCs. It also provides vaccine potential of PVCs in terms of their possible immunogenicity by comparing with experimentally known IEDB epitopes, absence of autoimmunity and conservation in different strains. Predicted PVCs are prioritized so that only few prospective PVCs could be validated experimentally. The performance of web server was evaluated against known protective antigens from diverse classes of bacteria reported in Protegen database and datasets used for VaxiJen server development. The web server efficiently predicted known vaccine candidates reported from Streptococcus pneumoniae and Escherichia coli proteomes. The Jenner-Predict server outperformed NERVE, Vaxign and VaxiJen methods. It has sensitivity of 0.774 and 0.711 for Protegen and VaxiJen dataset, respectively while specificity of 0.940 has been obtained for the latter dataset. CONCLUSIONS: Better prediction accuracy of Jenner-Predict web server signifies that domains involved in host-pathogen interactions and pathogenesis are better criteria for prediction of PVCs. The web server has successfully predicted maximum known PVCs belonging to different functional classes. Jenner-Predict server is freely accessible at http://117.211.115.67/vaccine/home.html.


Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Vacunas Bacterianas/inmunología , Interacciones Huésped-Patógeno , Programas Informáticos , Adhesinas Bacterianas/inmunología , Antígenos Bacterianos/química , Proteínas Bacterianas/química , Epítopos/inmunología , Escherichia coli/inmunología , Estructura Terciaria de Proteína , Proteoma/química , Proteoma/inmunología , Streptococcus pneumoniae/inmunología , Vacunas de Subunidad/inmunología , Factores de Virulencia/inmunología
15.
Life (Basel) ; 13(2)2023 Feb 16.
Artículo en Inglés | MEDLINE | ID: mdl-36836915

RESUMEN

Recently, mogrol has emerged as an important therapeutic candidate with multiple potential pharmacological properties, including neuroprotective, anticancer, anti-inflammatory, antiobesity, antidiabetes, and exerting a protective effect on different organs such as the lungs, bone, brain, and colon. Pharmacokinetic studies also highlighted the potential of mogrol as a therapeutic. Studies were also conducted to design and synthesize the analogs of mogrol to achieve better activities against different diseases. The literature also highlighted the possible molecular mechanism behind pharmacological activities, which suggested the role of several important targets, including AMPK, TNF-α, and NF-κB. These important mogrol targets were verified in different studies, indicating the possible role of mogrol in other associated diseases. Still, the compilation of pharmacological properties, possible molecular mechanisms, and important targets of the mogrol is missing in the literature. The current study not only provides the compilation of information regarding pharmacological activities but also highlights the current gaps and suggests the precise direction for the development of mogrol as a therapeutic against different diseases.

16.
Biomater Adv ; 148: 213363, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36881963

RESUMEN

Silver nanoparticles (AgNPs) have inconsistent findings against inflammation. Although a wealth of literature on the beneficial effects of green-synthesized AgNPs has been published, a detailed mechanistic study of green AgNPs on the protective effects against lipopolysaccharide (LPS)-induced neuroinflammation using human microglial cells (HMC3) has not yet been reported. For the first time, we studied the inhibitory effect of biogenic AgNPs on inflammation and oxidative stress induced by LPS in HMC3 cells. X-ray photoelectron spectroscopy, Fourier-transform infrared spectroscopy, and transmission electron microscopy were used to characterize AgNPs produced from honeyberry. Co-treatment with AgNPs significantly reduced mRNA expressions of inflammatory molecules such as interleukin (IL)-6 and tumor necrosis factor-α, while increasing the expressions of anti-inflammatory markers such as IL-10 and transforming growth factor (TGF)-ß. HMC3 cells were also switched from M1 to M2, as shown by lower expression of M1 markers such as cluster of differentiation (CD)80, CD86, and CD68 and higher expression of M2 markers such as CD206, CD163, and triggering receptors expressed on myeloid cells (TREM2). Furthermore, AgNPs inhibited LPS-induced toll-like receptor (TLR)4 signaling, as evidenced by decreased expression of myeloid differentiation factor 88 (MyD88) and TLR4. In addition, AgNPs reduced the production of reactive oxygen species (ROS) and enhanced the expression of nuclear factor-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1), while decreasing the expression of inducible nitric oxide synthase. The docking score of the honeyberry phytoconstituents ranged from -14.93 to - 4.28 KJ/mol. In conclusion, biogenic AgNPs protect against neuroinflammation and oxidative stress by targeting TLR4/MyD88 and Nrf2/HO-1 signaling pathways in a LPS-induced in vitro model. Biogenic AgNPs could be utilized as potential nanomedicine against LPS-induced inflammatory disorders.


Asunto(s)
Lipopolisacáridos , Nanopartículas del Metal , Humanos , Lipopolisacáridos/toxicidad , Factor 88 de Diferenciación Mieloide/genética , Factor 88 de Diferenciación Mieloide/metabolismo , Factor 88 de Diferenciación Mieloide/farmacología , Simulación del Acoplamiento Molecular , Plata/farmacología , Factor 2 Relacionado con NF-E2/genética , Factor 2 Relacionado con NF-E2/metabolismo , Factor 2 Relacionado con NF-E2/farmacología , Enfermedades Neuroinflamatorias , Hemo-Oxigenasa 1/genética , Hemo-Oxigenasa 1/metabolismo , Hemo-Oxigenasa 1/farmacología , Receptor Toll-Like 4/genética , Receptor Toll-Like 4/metabolismo , Nanopartículas del Metal/uso terapéutico , Transducción de Señal , Fenotipo , Línea Celular , Inflamación/inducido químicamente , Inflamación/metabolismo , Encéfalo/metabolismo
17.
Antioxidants (Basel) ; 11(12)2022 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-36552702

RESUMEN

Urtica dioica (UD) is a multi-functional plant known to be used as both food and medicine from ancient times. The plant has the potential to be used as a fertilizer and for biological pest control. It is also used in textile and related industries for its quality fibers. In the recent past, the plant has received great attention for its numerous important biological activities and food applications. The antioxidant activity of UD is the crucial factor supporting its important biological activities, such as anticancer, antidiabetic and anti-inflammatory properties. The antioxidant activity of UD is also found to be protective in different organs, including the brain, liver, lungs, kidney, ovary, and uterus, and may also be protective against diseases associated with these organs. Few clinical studies have endorsed the antioxidant potential of UD in patients. The current work is an attempt to comprehensively compile and discuss the antioxidant activity of UD from in vitro, in vivo and human studies. The insights of the current study would be helpful in getting a panoramic view of the antioxidant potential of UD, and provide direction for optimizing and developing it for therapeutic applications against important diseases and conditions in the near future.

18.
Front Immunol ; 13: 832106, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35444664

RESUMEN

Coronavirus disease 2019 (COVID-19) is the most devastating pandemic of the century, which is still far from over. The remarkable success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is the working hope, but the evolving variants are the huge concern that can turn the tide. Potential immune escape mutations (PIEMs) in the past and circulating variants were not studied at large scale (all available data). Hence, the conservation of antigenic determinants (epitopes) was analyzed in all available sequences of SARS-CoV-2 according to time (months), proteins, hosts, and variants. Numerous highly conserved B- and T-cell epitopes were identified in 24 proteins of SARS-CoV-2. A decrease in the conservation of epitopes with time was observed in almost all proteins, which was more rapid in neutralizing epitopes. Delta variant still has the highest PIEM in the circulating strains, which pose threat to the effectiveness of current vaccines. The inclusion of identified, highly conserved, and important epitopes in subunit vaccines can increase vaccine effectiveness against evolving variants. Trends in the conservation of epitopes in different proteins, hosts, and variants with time may also help to inspire the counter measure against the current pandemic.


Asunto(s)
COVID-19 , SARS-CoV-2 , COVID-19/prevención & control , Vacunas contra la COVID-19 , Epítopos de Linfocito T/genética , Humanos , SARS-CoV-2/genética , Glicoproteína de la Espiga del Coronavirus/genética , Vacunas de Subunidad
19.
Curr Drug Targets ; 23(1): 99-113, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34365920

RESUMEN

The Angiotensin II type 2 Receptor (AT2R) is one of the critical components of the renin- angiotensin system (RAS), which performs diverse functions like inhibiting cell differentiation, cell proliferation, vasodilatation, reduces oxidative stress and inflammation. AT2R is relatively less studied in comparison to other components of RAS despite its uniqueness (sex-linked) and diverse functions. The AT2R is differentially expressed in different tissues, and its gene polymorphisms are associated with several diseases. The molecular mechanism behind the association of AT2R and its gene polymorphisms with the diseases remains to be fully understood, which hinders the development of AT2R as a drug target. Single nucleotide polymorphisms (SNPs) in AT2R are found at different locations (exons, introns, promoter, and UTR regions) and were studied for association with different diseases. There may be different mechanisms behind these associations as some AT2R SNP variants were associated with differential expression, the SNPs (A1675G/ A1332G) affect the alternate splicing of AT2R mRNA, A1332G genotype results in shortening of the AT2R mRNA and subsequently defective protein. Few SNPs were found to be associated with the diseases in either females (C4599A) or males (T1334C). Several other SNPs were expected to be associated with other similar/related diseases, but studies have not been done yet. The present review emphasizes on the significance of AT2R and its polymorphisms associated with the diseases to explore the precise role of AT2R in different diseases and the possibility to develop AT2R as a potential drug target.


Asunto(s)
Hipertensión , Receptor de Angiotensina Tipo 2 , Femenino , Humanos , Hipertensión/genética , Masculino , Polimorfismo de Nucleótido Simple , ARN Mensajero/metabolismo , Receptor de Angiotensina Tipo 2/genética , Sistema Renina-Angiotensina/genética
20.
Recent Pat Biotechnol ; 16(1): 35-63, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34353275

RESUMEN

BACKGROUND: Humans can be infected with various coronaviruses that can cause serious illness and death. One such pandemic strain of coronavirus was recently identified in December 2019, and it led to a devastating outbreak in Wuhan city of China. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2). It is highly contagious and causes symptoms such as fever, cough, and shortness of breath. OBJECTIVE: The objective of this review is to highlight the current understanding, research, and therapeutic updates of the novel coronavirus disease 2019 (COVID-19). METHODS: A thorough literature search was conducted for research papers and patents in the context of COVID-19. All the related articles were extracted from various public repositories such as Google Scholar, Pubmed, ScienceDirect (Elsevier), Springer, Web of Science, etc. Results: The present analysis revealed that the key areas of the inventions were vaccines and diagnostic kits apart from developing the treatment of CoV. It was also observed that no specific vaccine treatments were available for the treatment of 2019-nCov; therefore, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV. The current focus of the researches has turned towards developing four potential treatments, including the development of candidate vaccines, development of novel potential drugs, repurposing of existing drugs, and development of convalescent plasma therapy. The PCR based diagnosis is the gold standard for the COVID-19 testing, but it requires resource time, expertise, and high associated cost; hence researchers are also developing different diagnostic methods for the COVID-19. Although vaccines are being developed by various companies and have passed the pre-clinical stages but there still exists no guarantee for these to come into effect. The current treatments that are being used for COVID-19 patients are not well established and have shown limited success. CONCLUSION: The pandemic has challenged the medical, economic, and public health infrastructure across the globe. There is an urgent need to explore all available and possible methods/ approaches to study this disease for drug and vaccine development at the earliest.


Asunto(s)
COVID-19 , Vacunas , COVID-19/terapia , Prueba de COVID-19 , Humanos , Inmunización Pasiva , Patentes como Asunto , SARS-CoV-2 , Sueroterapia para COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA